SCHEMBL4771243

SCHEMBL4771243

CCC1c2nccnc2CCN1C(=O)Oc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CHRNA7 P36544 1/20 0.41
HTR3A P46098 1/20 0.41
PABPC1 P11940 1/20 0.41
GAA P10253 2/20 0.40
PARP1 P09874 1/20 0.40
AOC3 Q16853 1/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
MAPK1 P28482 2/20 0.37
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775918 0.80 GPR119 (0.38) ALDH1A1PARP1NPC1KDM4E
SCHEMBL5697162 0.70 ALDH1A1 (0.63) SMN1; SMN2ALDH1A1CHRNA7HTR3APABPC1
SCHEMBL31569291 0.67 POLB (0.41) PARP1CYP2C9KDM4E
SCHEMBL1501954 0.66 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1CHRNA7HTR3APABPC1
SCHEMBL11477105 0.65 PTGDR2 (0.42) KDM4E
SCHEMBL7826263 0.64 GAA (0.51) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA
SCHEMBL10089213 0.64 GAA (0.70) GAANPC1RAB9A
SCHEMBL11486774 0.63 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1CHRNA7HTR3APABPC1
SCHEMBL5697246 0.62 ALDH1A1 (0.68) SMN1; SMN2ALDH1A1CHRNA7HTR3APABPC1
SCHEMBL23879291 0.62 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1CHRNA7HTR3AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592689-A4 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO INC (US) 2008-12-24 EP disclosed
US-7388019-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2008-06-17 US disclosed
US-20060074087-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2006-04-06 US disclosed
EP-1592689-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2005-11-09 EP disclosed
WO-2004069162-A2 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074087-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 SMN1; SMN2 4201/4885ALDH1A1 686/4885CHRNA7 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.